H. Oshima

Empagliflozin, an SGLT2 Inhibitor, Reduced the Mortality Rate after Acute Myocardial Infarction with Modification of Cardiac Metabolomes and Antioxidants in Diabetic Rats

M. Mizuno, T. Miura, Tatsuya Sato, 2018, The Journal of Pharmacology and Experimental Therapeutics.

Empagliflozin normalizes the size and number of mitochondria and prevents reduction in mitochondrial size after myocardial infarction in diabetic hearts

M. Mizuno, T. Miura, Tatsuya Sato, 2018, Physiological reports.

Empagliflozin attenuates acute kidney injury after myocardial infarction in diabetic rats

M. Mizuno, Marenao Tanaka, N. Moniwa, 2020, Scientific Reports.

Distinct impacts of sleep-disordered breathing on glycemic variability in patients with and without diabetes mellitus

M. Mizuno, T. Miura, H. Ohnishi, 2017, PloS one.

Accuracy of flash glucose monitoring in insulin‐treated patients with type 2 diabetes

M. Furuhashi, T. Miura, Tatsuya Sato, 2018, Journal of diabetes investigation.

Reply to the comment of Hirota et al. on “Accuracy of flash glucose monitoring in insulin‐treated patients with type 2 diabetes”

M. Furuhashi, T. Miura, Tatsuya Sato, 2019, Journal of diabetes investigation.

Inactive cardiac sarcoidosis with characteristic findings on cardiac MRI

S. Kodera, J. Kanda, Yusuke S. Hori, 2013, BMJ Case Reports.

Empagliflozin attenuates acute kidney injury after myocardial infarction in diabetic rats

M. Mizuno, Marenao Tanaka, N. Moniwa, 2020, Scientific Reports.

Late gadolinium enhancement image masquerading as hypertrophic cardiomyopathy in Fabry disease receiving enzyme replacement therapy.

Marenao Tanaka, T. Miura, T. Miki, 2016, International journal of cardiology.